Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvon Protection Regulatory News (AVON)

Share Price Information for Avon Protection (AVON)

Share Price is delayed by 15 minutes
Get Live Data
1,654.00    -60.00 (-3.50%)
Bid:
1,664.00
Ask:
1,678.00
Spread: 14.00 (0.841%)
Market Cap: £487.13m
AVON Live PriceLast checked at - London Stock Exchange

Intraday Avon Protection Share Chart

Post Close Trading Update

13 Oct 2021 07:00

RNS Number : 8651O
Avon Protection PLC
13 October 2021
 

13 October 2021

Avon Protection plc

Post Close Trading Update

 

Avon Protection plc ("Avon" or the "Group") today provides the following post close trading update for its financial year ended 30 September 2021 ("FY21").

 

Trading update

Avon has continued to see good commercial momentum in the second half of FY21, with order intake for the year of c.$280 million. This represents total year-on-year order growth of 34% and growth of 15% excluding Team Wendy. As a result, the Group has carried a strong closing order book of $141 million into the new financial year ("FY22"), up 39% on 30 September 2020. This momentum underpins confidence in the Group's growth expectations for FY22.

 

The Group expects to report revenue of $250 million for FY21 (2020: $213.6 million), which is within the range indicated in our trading update of 13 August 2021. This includes a Team Wendy contribution of $41 million from the first 11 months of ownership, in line with expectations at the time of acquisition.

 

As expected, we have seen revenue growth in our First Responder business and Military respiratory portfolio, offset by declines in Military ballistic revenue due to the previously announced delays. Overall, Military revenue is expected to decline by 3% to $149 million with respiratory revenue growth of 10% being offset by a 31% decline in Military ballistic revenues. First Responder revenues are expected to have increased by 2% to $61 million, against a strong comparator in 2020, driven by very encouraging growth in our ballistic protection portfolio.

 

Trading profitability in the remainder of FY21 was in line with the expectations set out in the August trading update. The Group will however recognise one-off, non-cash, ballistic protection inventory adjustments, which are expected to reduce the reported adjusted EBITDA margin for FY21 to between 15% and 16%.

 

Cash conversion has come through more strongly than anticipated at the time of the August trading update. As a result, we expect FY21 reported cash conversion of c.80% and net debt before lease liabilities of $27 million at 30 September 2021.

 

Commenting, Paul McDonald, Chief Executive Officer, said:

"We have made considerable commercial progress over the last 12 months in continuing to build a broader portfolio of contracts, increasing our pipeline of opportunities and making record levels of investment in the business.

 

We carry significant commercial momentum into FY22, which will also benefit from a strong ramp-up in body armor, as well as the strengthened senior management, processes and infrastructure we have put in place over the past year whilst navigating the ongoing disruption related to Covid through our supply chains.

 

We remain well set for growth in FY22 and beyond and are as confident as ever about the medium-term prospects of Avon Protection. This is underpinned by a strong order book, a growing and visible contract pipeline and our global market leading positions in respiratory and ballistic protection."

 

Notice of Results

The Group will release its results for the year ended 30 September 2021 on 23 November 2021.

 

For further enquiries, please contact:

 

Avon Protection plc

Paul McDonald, Chief Executive Officer

01225 896 848

Nick Keveth, Chief Financial Officer

Rachel Stevens, Director of Investor Relations

MHP Communications

Andrew Jaques

0203 128 8570

Charlie Barker

avonprotection@mhpc.com

Pete Lambie

 

Legal Entity Identifier: 213800JM1AN62REBWA71

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

Note to editors: 

Avon Protection plc is listed on the London Stock Exchange (LSE: AVON) and is an innovative technology group, which designs and produces life critical personal protection systems to maximise the performance and capabilities of its customers, with leading positions in the respiratory and ballistic protection markets for the world's militaries and first responders.

For further information, please visit our website www.avon-protection-plc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFETIDLFLIL
Date   Source Headline
8th Feb 20227:00 amRNSTransaction in Own Shares
7th Feb 20225:00 pmRNSDirector/PDMR Shareholding
7th Feb 20227:00 amRNSTransaction in Own Shares
4th Feb 20227:00 amRNSTransaction in Own Shares
3rd Feb 20226:00 pmRNSHolding(s) in Company
3rd Feb 20226:00 pmRNSHolding(s) in Company
3rd Feb 20227:00 amRNSTransaction in Own Shares
2nd Feb 20221:30 pmRNSDirector/PDMR Shareholding
31st Jan 20227:00 amRNSTransaction in Own Shares
28th Jan 20221:00 pmRNSResult of AGM
28th Jan 20227:00 amRNSLaunch of Share Buyback Programme
28th Jan 20227:00 amRNSAnnual General Meeting - Trading Update
21st Jan 20227:01 amEQSEdison Investment Research Limited: Avon Protection (AVON): Refocused Protection set to resume growth
19th Jan 202211:00 amRNSAGM update
14th Jan 20224:00 pmRNSDirector/PDMR Shareholding
6th Jan 20227:00 amRNSChief Financial Officer Appointment
21st Dec 20212:00 pmRNSDirector/PDMR Shareholding
21st Dec 20212:00 pmRNSDirector/PDMR Shareholding
17th Dec 20214:00 pmRNSNotice of Annual Report and AGM
16th Dec 20215:00 pmRNSHolding(s) in Company
15th Dec 20213:00 pmRNSDirector/PDMR Shareholding
15th Dec 20217:00 amRNSFinal Results
7th Dec 20214:00 pmRNSDirector/PDMR Shareholding
2nd Dec 20217:00 amRNSNotice of Results
17th Nov 20213:00 pmRNSHolding(s) in Company
16th Nov 20216:00 pmRNSHolding(s) in Company
16th Nov 20212:00 pmRNSHolding(s) in Company
16th Nov 202112:00 pmRNSHolding(s) in Company
16th Nov 20219:00 amRNSHolding(s) in Company
12th Nov 20217:00 amRNSBody armor strategic review
9th Nov 202111:00 amRNSDirector/PDMR Shareholding
13th Oct 20213:00 pmRNSDirector/PDMR Shareholding
13th Oct 20217:00 amRNSPost Close Trading Update
27th Sep 20216:00 pmRNSDirector/PDMR Shareholding
27th Sep 20215:00 pmRNSHolding(s) in Company
24th Sep 20213:00 pmRNSDirector/PDMR Shareholding
24th Sep 20217:00 amRNSU.S. Defense Logistics Agency Body Armor Contract
17th Sep 20216:00 pmRNSHolding(s) in Company
17th Sep 20214:00 pmRNSHolding(s) in Company
8th Sep 20211:00 pmRNSDirector/PDMR Shareholding
8th Sep 20217:00 amRNSU.S. DOD next generation ballistic helmet contract
31st Aug 20215:00 pmRNSHolding(s) in Company
31st Aug 20214:00 pmRNSHolding(s) in Company
18th Aug 20217:00 amRNSHolding(s) in Company
16th Aug 20217:00 amRNSExchange Rate for Interim Dividend
13th Aug 20219:00 amRNSHolding(s) in Company
13th Aug 20217:00 amRNSTrading Update
6th Aug 202111:00 amRNSDirector/PDMR Shareholding
14th Jul 20217:00 amRNSChange of Company Name
12th Jul 20215:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.